Medical Necessity Assessment for Gammagard in ITP

Key Clinical Decision Points

The American Society of Hematology 2019 guidelines state that treatment in ITP should aim for hemostatic platelet counts rather than normal counts, and asymptomatic patients with platelet levels of 34,000-40,000/mcL do not require intervention 1
The ASH 2011 and 2019 guidelines emphasize that treatment decisions should be based on bleeding risk and symptoms, not platelet count alone, for patients with no documented bleeding, no petechiae, no bruising, and no hemorrhagic complications 2, 3
The International Consensus Report states that treatment is primarily indicated when platelet counts are <30,000/mcL AND there are significant bleeding symptoms, high bleeding risk, or need for rapid platelet increase 4, 5

IVIG is reserved for specific urgent situations in ITP, such as active bleeding with thrombocytopenia, requiring rapid platelet elevation 4, 5, 6
IVIG is indicated for pre-procedural preparation when invasive procedures or surgery are planned and rapid platelet increase is needed to achieve hemostatic levels 4, 6
IVIG is considered when first-line corticosteroid therapy has failed or cannot be used due to contraindications 5
IVIG is used in emergency situations, such as life-threatening bleeding, intracranial hemorrhage risk, or trauma requiring immediate platelet elevation 4, 6

The ASH 2011 guidelines recommend that asymptomatic patients with counts >30,000/mcL typically do not require intervention 2, 3
The International Consensus Report confirms that the goal of all treatment strategies for ITP is to achieve a platelet count associated with adequate hemostasis, rather than a 'normal' platelet count 4
First-line therapy should be corticosteroids, not IVIG, with IVIG added only if corticosteroids fail, are contraindicated, or if rapid platelet elevation is urgently needed 5, 6, 7

The American Society of Hematology guidelines warn against treating platelet counts in isolation, instead emphasizing the importance of clinical bleeding risk 2, 4
The use of IVIG carries significant risks, including renal failure, thrombosis, aseptic meningitis, and hemolysis, which are not justified in an asymptomatic patient 5, 6